DAX23.881 +0,6%ESt505.530 +0,4%Top 10 Crypto15,85 -0,4%Dow46.398 +0,2%Nas22.660 +0,3%Bitcoin97.534 +0,4%Euro1,1735 ±-0,0%Öl66,17 -1,3%Gold3.866 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 Lufthansa 823212 RENK RENK73 Wolfspeed A41JEH NVIDIA 918422 HENSOLDT HAG000 Alibaba A117ME Novo Nordisk A3EU6F Tesla A1CX3T Siemens Energy ENER6Y BYD A0M4W9 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown droht: US-Börsen schließen dennoch höher -- DAX letztlich fester -- CoreWeave, Meta, Lufthansa, Continental, Alibaba, Tilray, Clara Technologies, Wolfspeed, Firefly, Etsy, Shopify im Fokus
Top News
NVIDIA-Aktie nach Milliardendeal im Fokus: Zwischen Kursfantasie und Bedenken NVIDIA-Aktie nach Milliardendeal im Fokus: Zwischen Kursfantasie und Bedenken
September 2025: So performten die einzelnen DAX-Aktien im vergangenen Monat September 2025: So performten die einzelnen DAX-Aktien im vergangenen Monat
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Bleibt BNP Paribas weiter das beste Zertifikatehaus in Deutschland? Entscheiden Sie hier und ergreifen Sie dabei die Chance auf eine Reise nach Berlin.

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
157,52 EUR +2,52 EUR +1,63 %
BMN
185,40 USD +0,02 USD +0,01 %
nachbörslich
BTT
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.372,89 Mrd. EUR

KGV24,98Div. Rendite3,40%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
EN, Johnson & JohnsonU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
PR NewswireU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
EN, Johnson & JohnsonThe Johnson & Johnson Foundation Announces $5 Million Expanded Investment in Africa Frontline First Catalytic Fund to Strengthen the Community Health Workforce
Wer­bungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EN, Johnson & JohnsonJohnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR
EN, Johnson & JohnsonTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
PR NewswireTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
EN, Johnson & JohnsonJohnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
EN, Johnson & JohnsonTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
PR NewswireTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
EN, Johnson & JohnsonIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
PR NewswireIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
EN, Johnson & JohnsonJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson Announces Launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter in Europe to Transform Treatment of Difficult-to-Cross Calcified Lesions
PR NewswireJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
EN, Johnson & JohnsonU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
PR NewswireU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
EN, Johnson & JohnsonData published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
PR NewswireData published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
EN, Johnson & JohnsonRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
EN, Johnson & JohnsonNew real-world data elevating patient perspectives highlight the need for scientific advancement in maternal fetal immunology at ISUOG 2025
EN, Johnson & JohnsonJohnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
PR NewswireJohnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
PR NewswireNew Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
PR NewswireJohnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
PR NewswireJohnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active ...
PR NewswireJohnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
PR NewswireJohnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
PR NewswireSupplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo
PR NewswireIMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published in...
PR NewswireInvestigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
PR NewswireJohnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
PR NewswireNew results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
PR NewswireNew data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
PR NewswireEarly results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
PR NewswireSingle infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
PR NewswireDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma ...
PR NewswireJohnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
PR NewswireU.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
PR NewswireIcotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.